Biomarkers that add value early in drug development
The use of biomarkers has the potential to increase value early in drug development by extracting more data and information from each study. This can increase efficiency, reduce costs, guide decisions, boost the translational power of preclinical studies, and effectively enable more drug candidates to move forward. MD Biosciences has expertise with biomarker analysis for markers that play a role in neuroinflammation, neurodegeneration, and pain. The methods are listed below.
Preclinical and Clinical Biomarker Assays
-
Multiplex Analysis
Multiplex immunoassay panels measure up to 50 cytokines, chemokines and neuro markers from a single sample, typically under 25 µL, in plasma, serum, CSF and tissue lysates from rodent and pig studies. Panels are selected for each study around the markers that drive neuroinflammation, neurodegeneration and pain, and can be combined with single analyte immunoassays for markers such as NfL and BDNF.
-
ELISA
ELISA immunoassays are plate-based assays that detect and quantify target proteins. This tool offers high sensitivity and specificity for one analyte per run, while the multiplex assay can measure several markers per run.
-
Western Blot
MD Biosciences runs Western Blot services for target protein detection. Western Blot is an accurate and quantitative assay for analyzing protein expression in cells.
-
Flow Cytometry
MD Biosciences offers immunophenotyping by flow cytometry to assess efficacy, PK/PD and mechanism of action. Flow cytometry is the recommended analytical method to identify cell populations in blood and tissues.
Panels are pre-validated or custom validated for preclinical and clinical evaluation.

Click here for more information on histology services.
Explore Our Resources
Whitepaper: Translational Biomarkers
This whitepaper provides an overview of how biomarkers can be utilized to extract maximum value early in translational studies while being optimized for use in clinical studies.
Whitepaper: Inflammatory Biomarkers
The interplay between the central and peripheral nervous systems and the immune response highlights the importance of understanding the cellular and inflammatory attributes that are strongly associated with neurological diseases and pain.
Whitepaper: Biomarker Detection
Multiplex and ultra-sensitive detection assays provide a powerful platform for difficult to measure analytes. The detection of these markers offers invaluable insight on monitoring disease progression at earlier stages and assessing the need for therapeutic intervention.


